Waldenstrom's Macroglobulinemia

Mutation ID'd in Waldenstrom's macroglobulinemia

(HealthDay)—MYD88 L265P is a common, recurring mutation in patients with Waldenström's macroglobulinemia, according to a study published in the Aug. 30 issue of the New England Journal of Medicine.

Aug 30, 2012
popularity0 comments 0

Waldenström's macroglobulinemia (WM, also known as lymphoplasmacytic lymphoma) is cancer involving a subtype of white blood cells called B cells. The main attributing antibody is Immunoglobulin M (IgM). WM is an "indolent lymphoma," (i.e., one that tends to grow and spread slowly). It is a type of lymphoproliferative disease, which shares clinical characteristics with the indolent non-Hodgkin lymphomas.

The disease, named after the Swedish oncologist Jan G. Waldenström, was first identified in 1944. As with other lymphomas, the disease is characterized by an uncontrolled increase of B-cells, i.e., white blood cells formed in the bone marrow and lymph nodes. The proliferation of B-cells interferes with the production of red blood cells, resulting in anemia. A unique characteristic of the disease is that the B-cells produce excess amounts of immunoglobulin protein (IgM), thickening the blood, and requiring additional treatment. WM is a rare disease, with only about 1,500 cases per year in the U.S. While the disease is incurable, it is treatable. Because of its indolent nature, many patients are able to lead active lives, and, when treatment is required, may experience years of symptom-free remission.

This text uses material from Wikipedia licensed under CC BY-SA

Latest Spotlight News

The 'love hormone' may quiet tinnitus

(HealthDay)—People suffering from chronic ringing in the ears—called tinnitus—may find some relief by spraying the hormone oxytocin in their nose, a small initial study by Brazilian researchers suggests.

Science can shape healthy city planning

Previous studies have shown a correlation between the design of cities and growing epidemics of injuries and non-communicable diseases such as heart disease, diabetes and cancer. A three-part series published in The Lancet ...

Unique molecular atlas of pancreas produced

Researchers at Karolinska Institutet have managed to produce the first molecular map of the genes that are active in the various cells of the human pancreas. They have also revealed differences in genetic activity between ...

Controlling cell-fate decisions

Rafal Ciosk and his group at the FMI have identified an important link between the Notch signaling pathway and PRC2-mediated gene silencing. They showed that a fine balance between epigenetic silencing and signaling is crucial ...